Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Why Croda’s seed enhancement business is providing food for thought

Croda (CRDA) £46.40
Gain to date: 6.4%
Original entry point: Buy at £43.47, 15 February 2018
Chemicals business Croda (CRDA) has enjoyed further share price gains following a recent capital markets event, which focused on its small yet exciting seed enhancement business Incotec.
Incotec was acquired in 2015 and focuses on maximising seed performance through a range of services, including disinfection, film coating, encrusting, pelleting and analytical quality testing.
This will improve the quality of vegetable and field crops, which is essential as agricultural productivity must increase by 60% over the next 30 years, according to Croda.
The shares could gain further momentum following a trading update on 25 April, which may reveal more sales growth in its personal care division.
Numis analyst Kevin Fogarty is impressed by Incotec’s seed enhancement tech, highlighting Croda is targeting a market worth $2.5bn, which is growing at 6% compound annual growth rate.
While Incotec is only a £50m revenue business at present, Fogarty notes Croda plans to boost growth by capitalising on macro themes of global population growth and threats to food production.
Croda is aiming to double the revenue base to approximately £100m and drive profit margins to over 20%, marking a substantial jump from Incotec’s initial margins of 10%.
Important information:
These articles are provided by Shares magazine which is published by AJ Bell Media, a part of AJ Bell. Shares is not written by AJ Bell.
Shares is provided for your general information and use and is not a personal recommendation to invest. It is not intended to be relied upon by you in making or not making any investment decisions. The investments referred to in these articles will not be suitable for all investors. If in doubt please seek appropriate independent financial advice.
Investors acting on the information in these articles do so at their own risk and AJ Bell Media and its staff do not accept liability for losses suffered by investors as a result of their investment decisions.
Issue contents
Big News
- JD Sports is still fighting fit
- ImmuPharma collapses on trial failure
- British Airways owner eyes takeover of Norwegian Air
- Apollo stalks FirstGroup with takeover interest
- Pound pushes to highest level since Brexit vote
- Cyber security firm Avast set for £2.8bn IPO
- Activist investor Elliott rumoured to have Micro Focus in its sights
- Costa spin-off calls at Whitbread gain momentum